📷 Image: Wikimedia Commons / Prime Minister's Office
Health
Tripura CM Introduces Emicizumab Prophylaxis for Haemophilia A Patients
✍️ TripuraTimes.com
🗓 12 Oct 2026, 03:01 AM
👁 9
The Chief Minister of Tripura announced the rollout of Emicizumab, a prophylactic therapy for people living with haemophilia A, aiming to reduce bleeding episodes across the state.
Tripura's Chief Minister officially launched the use of Emicizumab as a prophylactic treatment for patients diagnosed with haemophilia A. The announcement was made during a brief press interaction, emphasizing the government's commitment to addressing rare bleeding disorders.
Emicizumab is a monoclonal antibody that mimics the function of missing clotting factor VIII, thereby preventing spontaneous bleeds and reducing the need for frequent factor infusions. Clinical studies have shown it to lower the frequency of bleeding episodes and improve quality of life for sufferers.
The state health department said the drug will be made available through existing public hospitals and will be subsidised for eligible patients. Officials expect the initiative to benefit the small but significant cohort of haemophilia A patients residing in Tripura.
Health authorities noted that Emicizumab has received approval from the national drug regulator and its inclusion in the state programme reflects a broader push to enhance care for rare diseases in India.
Emicizumab is a monoclonal antibody that mimics the function of missing clotting factor VIII, thereby preventing spontaneous bleeds and reducing the need for frequent factor infusions. Clinical studies have shown it to lower the frequency of bleeding episodes and improve quality of life for sufferers.
The state health department said the drug will be made available through existing public hospitals and will be subsidised for eligible patients. Officials expect the initiative to benefit the small but significant cohort of haemophilia A patients residing in Tripura.
Health authorities noted that Emicizumab has received approval from the national drug regulator and its inclusion in the state programme reflects a broader push to enhance care for rare diseases in India.